Patient-reported outcomes following treatment with the human GLP-1 analogue liraglutide or glimepiride in monotherapy: results from a randomized controlled trial in patients with type 2 diabetes.

Bode BW, Testa MA, Magwire M, Hale PM, Hammer M, Blonde L, Garber A

Diabetes, obesity & metabolism1 Jul 2010Cited by 62 (Europe PMC)

PMID20590735PMCIDPMC2901519DOI10.1111/j.1463-1326.2010.01196.xPepBankPUB-20590735

Summary

AimAs weight gain and hypoglycaemia associated with glimepiride therapy can negatively impact weight perceptions, psychological well-being and overall quality of life in type 2 diabetes, we investigated whether liraglutide treatment could improve these factors.MethodsSeven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).ResultsMean (SE) decreases in glycated haemoglobin levels were greater with liraglutide 1.2 mg [-0.84 (0.08)%] and 1.8 mg [-1.14 (0.08)%] than glimepiride [-0.51 (0.08)%; p = 0.0014 and p < 0.0001, respectively]. Patients gained weight on glimepiride [mean (SE), 1.12 (0.27) kg] but lost weight on liraglutide [1.2 mg: -2.05 (0.28) kg; 1.8 mg: -2.45 (0.28) kg; both p < 0.0001]. Patient weight assessment was more favourable with liraglutide 1.8 mg [mean (SE) score: 40.0 (2.0)] than glimepiride [48.7 (2.0); p = 0.002], and liraglutide 1.8 mg patients were 52% less likely to feel overweight [odds ratio (OR) 0.48; 95% confidence interval (CI): 0.331-0.696]. Mean (SE) weight concerns were less with liraglutide [1.2 mg: 30.0 (1.2); 1.8 mg: 32.8 (1.2)] than glimepiride [38.8 (1.2); p < 0.0001 and p < 0.001, respectively], with liraglutide groups 45% less likely to report weight concern (OR 0.55, 95% CI: 0.41-0.73). Mean (SE) mental and emotional health and general perceived health improved more with liraglutide 1.8 mg [476.1 (2.8) and 444.2 (3.2), respectively] than glimepiride [466.3 (2.8) and 434.5 (3.2), respectively; p = 0.012 and p = 0.033, respectively].ConclusionsImproved glycaemic control and decreased weight with liraglutide 1.8 mg vs. glimepiride can improve psychological and emotional well-being and health perceptions by reducing anxiety and worry associated with weight gain.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study11

11 results from studies that gave the peptide. 11 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.2 mg decreased HbA1c more than glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than glimepiride.
Peptide
Liraglutide
Outcome
DecreaseHbA1c decrease, 1.2 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.2 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c change
−0.84%
liraglutide 1.2 mg
HbA1c change
−0.51%
glimepiride
Source sentences
Summary
Mean (SE) decreases in glycated haemoglobin levels were greater with liraglutide 1.2 mg [-0.84 (0.08)%] and 1.8 mg [-1.14 (0.08)%] than glimepiride [-0.51 (0.08)%; p = 0.0014 and p < 0.0001, respectively].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073501
02HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide 1.8 mg decreased HbA1c more than glimepiride.
In plain wordsIn adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than glimepiride.
Peptide
Liraglutide
Outcome
DecreaseHbA1c decrease, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Glycemic control · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
HbA1c change
−1.14%
liraglutide 1.8 mg
HbA1c change
−0.51%
glimepiride
Source sentences
Summary
Mean (SE) decreases in glycated haemoglobin levels were greater with liraglutide 1.2 mg [-0.84 (0.08)%] and 1.8 mg [-1.14 (0.08)%] than glimepiride [-0.51 (0.08)%; p = 0.0014 and p < 0.0001, respectively].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073502
03HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, patients lost weight on liraglutide 1.2 mg but gained weight on glimepiride.
In plain wordsIn adults with type 2 diabetes, people lost weight on liraglutide 1.2 mg but gained weight on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, 1.2 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.2 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−2.05 kg
liraglutide 1.2 mg
Weight change
1.12 kg
glimepiride
Source sentences
Summary
Patients gained weight on glimepiride [mean (SE), 1.12 (0.27) kg] but lost weight on liraglutide [1.2 mg: -2.05 (0.28) kg; 1.8 mg: -2.45 (0.28) kg; both p < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073503
04HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, patients lost weight on liraglutide 1.8 mg but gained weight on glimepiride.
In plain wordsIn adults with type 2 diabetes, people lost weight on liraglutide 1.8 mg but gained weight on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseBody weight change, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Body weight · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight change
−2.45 kg
liraglutide 1.8 mg
Weight change
1.12 kg
glimepiride
Source sentences
Summary
Patients gained weight on glimepiride [mean (SE), 1.12 (0.27) kg] but lost weight on liraglutide [1.2 mg: -2.05 (0.28) kg; 1.8 mg: -2.45 (0.28) kg; both p < 0.0001].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073504
05HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, patient weight assessment scores were more favourable with liraglutide 1.8 mg than with glimepiride.
In plain wordsIn adults with type 2 diabetes, people on liraglutide 1.8 mg rated their weight more favourably than people on glimepiride.
Peptide
Liraglutide
Outcome
DecreasePatient weight assessment score, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight assessment score
40 score
liraglutide 1.8 mg
Weight assessment score
48.7 score
glimepiride
Source sentences
Summary
Patient weight assessment was more favourable with liraglutide 1.8 mg [mean (SE) score: 40.0 (2.0)] than glimepiride [48.7 (2.0); p = 0.002]
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073505
06HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, patients on liraglutide 1.8 mg were 52% less likely to feel overweight than those on glimepiride.
In plain wordsIn adults with type 2 diabetes, people on liraglutide 1.8 mg were less likely to feel overweight than people on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseLikelihood of feeling overweight, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Metabolic and weight
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Odds ratio, feeling overweight
0.48 OR
liraglutide 1.8 mg vs glimepiride
Source sentences
Summary
and liraglutide 1.8 mg patients were 52% less likely to feel overweight [odds ratio (OR) 0.48; 95% confidence interval (CI): 0.331-0.696].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073506
07HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, weight concerns scores were lower with liraglutide 1.2 mg than with glimepiride.
In plain wordsIn adults with type 2 diabetes, people on liraglutide 1.2 mg had fewer weight concerns than people on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseWeight concerns score, 1.2 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
1.2 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight concerns score
30 score
liraglutide 1.2 mg
Weight concerns score
38.8 score
glimepiride
Source sentences
Summary
Mean (SE) weight concerns were less with liraglutide [1.2 mg: 30.0 (1.2); 1.8 mg: 32.8 (1.2)] than glimepiride [38.8 (1.2); p < 0.0001 and p < 0.001, respectively]
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073507
08HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, weight concerns scores were lower with liraglutide 1.8 mg than with glimepiride.
In plain wordsIn adults with type 2 diabetes, people on liraglutide 1.8 mg had fewer weight concerns than people on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseWeight concerns score, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Weight concerns score
32.8 score
liraglutide 1.8 mg
Weight concerns score
38.8 score
glimepiride
Source sentences
Summary
Mean (SE) weight concerns were less with liraglutide [1.2 mg: 30.0 (1.2); 1.8 mg: 32.8 (1.2)] than glimepiride [38.8 (1.2); p < 0.0001 and p < 0.001, respectively]
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073508
09HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, liraglutide groups were 45% less likely to report weight concern than the glimepiride group.
In plain wordsIn adults with type 2 diabetes, people on liraglutide were less likely to report weight concern than people on glimepiride.
Peptide
Liraglutide
Outcome
DecreaseLikelihood of reporting weight concern, both doses
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
1.2 and 1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Odds ratio, weight concern
0.55 OR
liraglutide groups vs glimepiride
Source sentences
Summary
with liraglutide groups 45% less likely to report weight concern (OR 0.55, 95% CI: 0.41-0.73).
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073509
10HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, mental and emotional health improved more with liraglutide 1.8 mg than with glimepiride.
In plain wordsIn adults with type 2 diabetes, mental and emotional health improved more on liraglutide 1.8 mg than on glimepiride.
Peptide
Liraglutide
Outcome
IncreaseMental and emotional health score, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Mental health and mood
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
Mental and emotional health score
476.1 score
liraglutide 1.8 mg
Mental and emotional health score
466.3 score
glimepiride
Source sentences
Summary
Mean (SE) mental and emotional health and general perceived health improved more with liraglutide 1.8 mg [476.1 (2.8) and 444.2 (3.2), respectively] than glimepiride [466.3 (2.8) and 434.5 (3.2), respectively; p = 0.012 and p = 0.033, respectively].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073510
11HumanRandomized controlled trialEfficacy outcome
In adults with type 2 diabetes, general perceived health improved more with liraglutide 1.8 mg than with glimepiride.
In plain wordsIn adults with type 2 diabetes, general perceived health improved more on liraglutide 1.8 mg than on glimepiride.
Peptide
Liraglutide
Outcome
IncreaseGeneral perceived health score, 1.8 mg
Study
n: not reported in source
Comparator
Glimepiride 8 mg
Outcome group
Patient-reported outcomes · Whole body
Studied dose
1.8 mg · subcutaneous · 52 weeksAs given in this study (human).
Measurements
General perceived health score
444.2 score
liraglutide 1.8 mg
General perceived health score
434.5 score
glimepiride
Source sentences
Summary
Mean (SE) mental and emotional health and general perceived health improved more with liraglutide 1.8 mg [476.1 (2.8) and 444.2 (3.2), respectively] than glimepiride [466.3 (2.8) and 434.5 (3.2), respectively; p = 0.012 and p = 0.033, respectively].
1 context sentence(design, population, supporting numbers)
Summary · context
Seven hundred and thirty-two patients with type 2 diabetes completed a 77-item questionnaire during a randomized, 52-week, double-blind study with liraglutide 1.2 mg (n = 245) or 1.8 mg (n = 242) compared with glimepiride 8 mg (n = 245).
Show in the study text Report a problemFND-2059073511

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 stopped early · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

TerminatedPhase 3Results postedNCT00294723

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Novo Nordisk A/Sn = 746Feb 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial page ClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 12:10 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.